Discover
ENTA
Enanta Pharmaceuticals, Inc.
14.77
2 x 10.73
2 x 18.90
bid
ask
+
0.19
1.30%
2 @ 04:00 PM
14.77 +0.00 (0.00%)
| Ytd | -6.34% | |
| 1y | 91.82% |
14.63
day range
15.20
6.43
52 week range
17.15
| Open | 14.63 | Prev Close | 14.58 | Low | 14.63 | High | 15.20 | Mkt Cap | 429.49M |
| Vol | 198.52K | Avg Vol | 199.32K | EPS | -2.60 | P/E | N/A | Forward P/E | -1.32 |
| Beta | 0.57 | Short Ratio | 20.91 | Inst. Own | 100.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 13.36 | 200-d Avg | 12.91 | 1yr Est | 16.88 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-02-05 | 2024-12 | -1.15 | N/A | N/A | N/A |
| 2024-11-25 | 2024-09 | -1.16 | -1.36 | -0.2 | -17.24% |
| 2024-08-05 | 2024-06 | -1.49 | -1.07 | 0.42 | 28.19% |
| 2024-05-06 | 2024-03 | -1.26 | -1.47 | -0.21 | -16.67% |
| 2024-02-07 | 2023-12 | -1.18 | -1.58 | -0.4 | -33.90% |
| 2023-11-20 | 2023-09 | -2.11 | -1.33 | 0.78 | 36.97% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-26 | Baird | Upgrade | Outperform | Outperform |
| 2024-11-26 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-10-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-09 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-09-27 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-08-06 | JP Morgan | Upgrade | Underweight | Underweight |
Profile
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-02-25 | GARDINER NATHANIEL S | Officer | 111.61K | Conversion of Exercise of derivative security |
| 2024-12-05 | KIEFFER TARA LYNN | Officer | 29.31K | Sale |
| 2024-12-05 | LULY JAY R | Chief Executive Officer | 801.64K | Sale |
| 2024-12-05 | LUU BRENDAN | Officer | 36.05K | Sale |
| 2024-12-05 | MELLETT PAUL J JR | Chief Financial Officer | 91.71K | Sale |
| 2024-12-05 | OR YAT SUN | Officer | 369.11K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Farallon Capital Management LLC | 2.11M | 13.43M | 9.95% |
| 2024-09-29 | Vanguard Group Inc | 1.98M | 12.62M | 9.35% |
| 2024-09-29 | Blackrock Inc. | 1.90M | 12.11M | 8.97% |
| 2024-09-29 | Krensavage Asset Management, LLC | 1.50M | 9.54M | 7.07% |
| 2024-09-29 | Morgan Stanley | 1.10M | 7.03M | 5.20% |
| 2024-09-29 | Armistice Capital, LLC | 1000.00K | 6.37M | 4.72% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 629.60K | 4.01M | 2.97% |
| 2024-10-30 | iShares Russell 2000 ETF | 524.38K | 3.34M | 2.47% |
| 2024-09-29 | Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 300.76K | 1.92M | 1.42% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 281.61K | 1.79M | 1.33% |
| 2024-09-29 | Vanguard Variable Insurance Fund-Small Company Growth | 253.37K | 1.61M | 1.20% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 203.26K | 1.29M | 0.96% |